Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology ...

1Department of Medicine, Weill Cornell Medicine, New York, New York. 2Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York.

1Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois. 2Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, Illinois.

"TRAF1 plays a central role in immune signaling and is known for its dual roles: it helps amplify inflammatory signaling in some contexts while also acting as a brake to limit overactive responses ...

In addition, we are able to incorporate co-stimulatory signaling into our T cell engager ... which consists of a T cell engager with a masked CD3 targeting domain, and tri-specific molecules ...

Despite advancements, the precise impact of T cell receptor (TCR) stimulation on this process remains incompletely understood. This study explores how TCR-CD3 signaling strength influences naive CD4 + ...